• Company
• Rozanolixizumab has been designated as an orphan drug
• by Eo, Yun-Ho Jun 14, 2023 05:37am

• Company
• Ildong makes initial lead in the SGLT2·DPP4 combo market
• by Kim, Jin-Gu Jun 14, 2023 05:35am

• Policy
• Handok's Imported Monjuvi Licensed
• by Lee, Hye-Kyung Jun 13, 2023 07:39pm

• Company
• Discussions on expanding benefit for Jakavi's GVHD are slow
• by Eo, Yun-Ho Jun 13, 2023 05:43am

• Company
• Severe asthma Tx Tezpire to soon be commercialized in Korea
• by Eo, Yun-Ho Jun 13, 2023 05:43am

• Opinion
• [Reporter's view] It's time to share the achievements
• by Lee, Seok-Jun Jun 13, 2023 05:43am

• Company
• Sales of Soliris and Ultomiris rise despite changes
• by Kim, Jin-Gu Jun 13, 2023 05:43am

• Company
• Beova can be prescribed at general hospitals
• by Eo, Yun-Ho Jun 12, 2023 05:42am

• Company
• Eisai applies for approval of its AD drug lecanemab in KOR
• by Jung, Sae-Im Jun 12, 2023 05:42am

• Company
• Fidanacogene Elaparvovec designated as an orphan drug
• by Eo, Yun-Ho Jun 12, 2023 05:42am